Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX

ESMO Open

article

J. Hyung¹  H. Lee²  H. Jin³  S. Lee³  H.J. Lee²  G. Gong²  T.J. Song⁴  S.S. Lee⁴  D.W. Hwang⁵  S.C. Kim⁵  J.H. Jeong¹  B.-Y. Ryoo¹  K. Kim¹  C. Yoo¹ 

[1] Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine;Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine;Department of Convergence Medicine, Asan Medical Center, University of Ulsan College of Medicine;Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine;Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine

关键词: pancreatic cancer;    TGF-β;    peripheral immune phenotype;    immune gene expression profile;   

DOI  :  10.1016/j.esmoop.2022.100484

学科分类：社会科学、人文和艺术（综合）

来源: BMJ Publishing Group

【 摘 要 】

Background A comprehensive analysis of peripheral immune cell phenotypes and tumor immune-gene expression profiles in locally advanced pancreatic cancer patients treated with neoadjuvant chemotherapy in a phase II clinical trial was carried out.Methods 10 months (achieved versus failed). Differential expression and pathway analysis of immune-related genes were carried out using the Nanostring platform, and immune cells within the tumor microenvironment were compared by immunohistochemistry.Results Forty-four patients were treated in the phase II clinical trial. Higher baseline CD14+CD11c+HLA-DR+ monocytes (P = 0.044) and lower Foxp3+CD4+ T cells (P = 0.02) were associated with poor progression-free survival of neoadjuvant mFOLFIRINOX. During the preoperative chemotherapy, PD-1 T cells significantly decreased (P = 0.0110). Differential expression and pathway analysis of immune-genes from the resected tumor after neoadjuvant treatment revealed transforming growth factor-β pathway enrichment and higher expression of MARCO (adjusted P < 0.05) associated with early recurrence. Enrichment of the Th1 pathway and higher peritumoral CD8+ T cells (P10 months) following neoadjuvant mFOLFIRINOX.Conclusions Our results identify potential immune biomarkers for locally advanced pancreatic cancer and provide insights into pancreatic cancer immunity.

【 授权许可】

CC BY|CC BY-NC-ND